Drug Profile
S 81694
Alternative Names: NMS P153; NMS-01940153E; NMS-153; S-81694Latest Information Update: 08 Dec 2022
Price :
$50
*
At a glance
- Originator Nerviano Medical Sciences
- Developer Nerviano Medical Sciences; Servier
- Class Antineoplastics; Small molecules
- Mechanism of Action TTK protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Breast cancer; Liver cancer
- Preclinical Acute myeloid leukaemia; Precursor B-cell lymphoblastic leukaemia-lymphoma
- No development reported Solid tumours
Most Recent Events
- 08 Dec 2022 Phase-I/II clinical trials in Liver cancer (Inoperable/Unresectable, Second-line therapy or greater, Monotherapy) in Italy (IV)
- 06 Dec 2022 Phase I/II is still ongoing for Liver cancer (Inoperable/unresectable, Second-line therapy or greater) in Italy (IV) (EduraCT-2020-001002-26)
- 26 Oct 2022 Efficacy, adverse events and pharmacokinetics data from phase I/II MPSA-153-001 trial in Liver cancer presented at 34th EORTC-NCI-AACR Symposium on molecular targets and cancer therapeutics (EORTC-NCI-AACR-2022)